title: Metabolic effects of diltiazem and atenolol: results from a randomized, double-blind study with parallel groups.
abstract: In a randomized, double-blind study (n = 58) with parallel groups, the effects of diltiazem (mean dose 329 mg/day) and atenolol (mean dose 67 mg/day) on carbohydrate and lipoprotein metabolism in hypertensive patients were compared. The mean systolic blood pressure (SBP)/diastolic blood pressure (DBP) reductions in the supine position were similar and satisfactory, 9/11 and 11/9 mmHg during atenolol and diltiazem treatment, respectively. Insulin-mediated glucose uptake, measured with the euglycaemic insulin clamp technique, decreased during atenolol treatment, from 7.1 to 5.6 mg/kg per min (P = 0.05). but not during treatment with diltiazem (initial value 6.8, final value 6.7 mg/kg per min; P greater than 0.8). Treatment differences between groups were statistically significant (P less than 0.05). During atenolol treatment there was a slight but significant increase in plasma glucose in the fasting state (P less than 0.05) and at the end of an intravenous glucose tolerance test (IVGTT; P less than 0.01), and in plasma insulin at the end of IVGTT (P less than 0.05). Despite increased insulin resistance the increase in insulin response was small, suggesting inhibition of insulin release. The insulin peak was decreased by 13% during diltiazem treatment (P less than 0.05). The concentrations of very-low and low-density lipoprotein triglycerides increased, whereas high-density lipoprotein cholesterol decreased and low-density lipoprotein cholesterol was unaffected during atenolol treatment. In conclusion, there was no difference between the antihypertensive effects of atenolol and diltiazem, but atenolol decreased insulin sensitivity and altered the lipid profile, thus possibly increasing the risk of diabetes mellitus and theoretically reducing the benefits of blood pressure reduction with regard to risk of coronary heart disease.
authors.affiliation: Department of Geriatrics, Uppsala University, Sweden.
authors.forename: T
authors.initials: T
authors.lastname: Pollare
authors.forename: H
authors.initials: H
authors.lastname: Lithell
authors.forename: C
authors.initials: C
authors.lastname: Mörlin
authors.forename: H
authors.initials: H
authors.lastname: Präntare
authors.forename: A
authors.initials: A
authors.lastname: Hvarfner
authors.forename: S
authors.initials: S
authors.lastname: Ljunghall
mesh_terms: D000328:Adult; D001262:Atenolol / Q000494:pharmacology*; D001786:Blood Glucose / Q000378:metabolism*; D002986:Clinical Trials as Topic; D004110:Diltiazem / Q000494:pharmacology*; D004311:Double-Blind Method; D005260:Female; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D006973:Hypertension / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D007328:Insulin / Q000097:blood*; D008074:Lipoproteins / Q000097:blood*; D008297:Male; D008875:Middle Aged; D011897:Random Allocation
chemical_list: D001786:Blood Glucose; D007328:Insulin; D008074:Lipoproteins; D001262:Atenolol; D004110:Diltiazem